Cytek Biosciences (CTKB) Operating Expenses (2020 - 2026)

Cytek Biosciences' Operating Expenses history runs 7 years deep, the most recent figure standing at $39.7 million for Q1 2026.

• Quarterly Operating Expenses rose 13.05% year-over-year to $39.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $149.4 million (up 12.34% YoY) and the FY2025 annual result came in at $144.8 million, up 10.04% from the prior year.
• Operating Expenses was $39.7 million for Q1 2026 at Cytek Biosciences, up from $38.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $39.7 million in Q1 2026 and bottomed at $22.5 million in Q1 2022.
• A 5-year average of $32.7 million and a median of $33.6 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses surged 68.74% — and 2024, when it decreased 8.92%.
• Cytek Biosciences' Operating Expenses stood at $29.3 million in 2022, then climbed by 13.3% to $33.2 million in 2023, then declined by 7.59% to $30.7 million in 2024, then grew by 25.48% to $38.5 million in 2025, then climbed by 3.22% to $39.7 million in 2026.
• Business Quant data shows CTKB's Operating Expenses at $39.7 million in Q1 2026, $38.5 million in Q4 2025, and $36.7 million in Q3 2025.